Is menstruation normal? Suppression of the menstrual cycle in clinical practice

Reproductive Medicine Review

Volumn 9, Issue 3, 2001, Pages 241-257

  Coutinho, E M ^a  

^a Centro De Pesquisa E Assistencia Em Reproducao Humana   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DANAZOL; ESTROGEN; GESTAGEN; GESTRINONE; GONADORELIN DERIVATIVE; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; STEROID;

ADULT; CLINICAL PRACTICE; DRUG INDUCED DISEASE; ENDOMETRIOSIS; FEMALE; HUMAN; HYSTERECTOMY; MENARCHE; MENSTRUAL CYCLE; MENSTRUATION; MYOMA; OVULATION; OVULATION INHIBITION; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; UTERUS BLEEDING;

EID: 0035739219     PISSN: 09622799     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0962279901000357     Document Type: Review

References (78)

1. Nuisance or natural and healthy: Should monthly menstruation be optional for women?
2. Is menstruation obsolete?
3. Is menstruation obsolete?
4. Who needs a period?
5. John Rock's error
6. Is a monthly period still necessary?
7. Blood simple
8. Growth hormone treatment during suppression of early puberty in adopted girls
9. Use of a combined Gn-RH agonist and hCG therapy for better attaining the goals in precocious puberty treatment
10. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty
11. Final height after long-term treatment with triptorelin slow release for central precocious puberty: Importance of statural growth after interruption of treatment
12. Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years
13. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist
14. Efficacy of Zoladex LA (goserelin) in the treatment of girls with central precocious or early puberty
15. Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot
16. Role of surgical resection in the treatment of hypothalamic hamartomas causing precocious puberty. Report of six cases
17. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: Long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty
18. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment
19. Randomized trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years
20. Lack of effect of GnRH agonists on final height in girls with advanced puberty: A randomized long-term pilot study
21. Bone age at discontinuation of medroxyprogesterone acetate therapy in girls with precocious puberty: Effect on final height
22. The potential impact of iron supplementation during adolescence on iron status in pregnancy
23. Iron requirements in adolescent females
24. Effectiveness and strategies of iron supplementation during pregnancy
25. Anemia in pregnancy
26. Maternal hemoglobin concentration and birth weight
27. Anemia, iron and pregnancy outcome
28. Anemia and iron deficiency: Effects on pregnancy outcome
29. Poorer behavioral and developmental outcome more than 10 years after treatment for iron deficiency in infancy
30. The appropriateness of recommendations for hysterectomy
31. Effectiveness of hysterectomy
32. Laparoscopic hysterectomy
33. Comparison of two procedures for laparovaginal hysterectomy: A randomized trial
34. Average charges for three types of hysterectomy procedures: United States, 1998
35. Total hysterectomy for benign pathologies: Direct costs comparison between laparoscopic and abdominal hysterectomy
36. A qualitative study of women's hysterectomy experience
37. Women's stories: Ethnic variations in women's attitudes and experiences of menopause, hysterectomy and hormone replacement therapy
38. Talking about hysterectomy: The experience of women from four culture groups
39. Decision making beliefs, and attitudes toward hysterectomy: A focus group with medically underserved women in Texas
40. Hysterectomy: What do women need and want to know?
41. Has endometrial ablation replaced hysterectomy for the treatment of dysfunctional uterine bleeding? National figures
42. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding
43. Menstrual blood loss measured 5-6 years after endometrial ablation
44. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: A nationwide study of 17,360 users
45. The effect of low-dose 3-keto-desogestrel added to a copper-releasing intrauterine contraceptive device on menstrual blood loss: A double blind, dose-finding, placebo-controlled study
46. Transvaginal ultrasonographic findings in the uterus and the endometrium: Low prevalence of leiomyoma in a random sample of women aged 25-40 years
47. Early normal menstrual cycle pattern and the development of uterine leiomyomas
48. Correlation between shrinkage of uterine leiomyomata treated with buserelin acetate and histopathologic findings of biopsy specimen before treatment
49. Long-term treatment of leiomyomas with gestrinone
50. Clinical management of leiomyomas with medroxyprogesterone acetate
51. Uterine artery embolisation for symptomatic fibroids
52. Danazol for pelvic pain associated with endometriosis
53. Treatment of endometriosis with gestrinone (R-2323), a synthetic anti-estrogen, anti-progesterone
54. Elcometrine for long-term contraception and clinical management of endometriosis
55. Gonadotropin-releasing hormone agonist treatment for endometriosis of the rectovaginal septum
56. Gonadotropin-releasing hormone analogues for pain associated with endometriosis
57. Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): A pilot study with low dose agonist therapy (draw back therapy)
58. Menstruation suppression in the treatment of catamenial diseases
59. Modern combined oral contraceptives for pain associated with endometriosis
60. Progestogens and anti-progestogens for pain associated with endometriosis
61. Extracts from the "clinical evidence". Endometriosis
62. Pituitary-ovarian dysfunction and endometriosis
63. Moderate and severe endometriosis is associated with alterations in the cell cycle of granulosa cells in patients undergoing in vitro fertilization and embryo transfer
64. Ovarian response to repeated controlled stimulation in in-vitro fertilization cycles in patients with ovarian endometriosis
65. Deep endometriosis conundrum: Evidence in favor of a peritoneal origin
66. Is ureteral endometriosis an asymmetric disease?
67. Sigmoid endometriosis and ovarian stimulation
68. Ovarian endometriosis associated with ovarian carcinoma: A clinicopathological and immunohistochemical study
69. Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors
70. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives
71. Premenstrual exacerbation and suicidal behavior in patients with panic disorder
72. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: A randomized, double-blind, cross-over study
73. Micronutrients and the premenstrual syndrome: The case for calcium
74. The treatment of severe premenstrual syndrome with goserelin with and without add-back therapy: A placebo-controlled study
75. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome
76. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use and replacement therapy use